During this segment, the panelists explore the use of personalized medicine in castration-resistant prostate cancer.
Jeffrey D. Dunn, PharmD, MBA, and Raoul S. Concepcion, MD, explain that clinicians hope to have better data available in the future to provide definitive answers about treatment options for specific patient populations.
Dr Concepcion explains the variables that are being reviewed to help clinicians make wiser treatment decisions for their patients.
However, E. David Crawford, MD, reminds the panelists why achieving this goal will not be easy.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More